Skip to main content
PLOS One logoLink to PLOS One
. 2025 Mar 10;20(3):e0319676. doi: 10.1371/journal.pone.0319676

Tuberculosis screening, isoniazid preventive therapy coverage and factors associated with active TB diagnosis among people living with HIV at public health facilities of central Ethiopia

Mecha Aboma 1,*, Bayisa Abdisa 1, Gudata Imana 1, Kefyalew Taye 1, Gonfa Moti 1, Merob Fufa 1
Editor: Rebecca F Baggaley2
PMCID: PMC11892821  PMID: 40063565

Abstract

Introduction

TB is the most frequent opportunistic infection and cause of death among People living with HIV/AIDS. Human immunodeficiency virus-positive individuals are routinely screened for tuberculosis as a means of monitoring efforts to mitigate the consequences of the disease on HIV-positive patients. TB status assessment identifies HIV-positive clients who show no evidence of active TB by symptom screening and would benefit from treatment with isoniazid for prevention of TB disease among HIV positives.

Methods

A facility-based cross-sectional study design was conducted in public health facilities of West Shewa Zone from January to February 2019. Of the 28 Public health facilities providing HIV/AIDS care and support (HCT and ART services) 13 of them were selected by simple random sampling techniques. Finally, 815 study participants were recruited by systematics sampling techniques & proportional sample size allocation was applied depending on the HIV patient load in each health facility. After reviewing relevant literature, a structured questionnaire adapted from standardized WHO guidelines, prepared for monitoring & evaluation of TB/HIV activities was used to collect data via interviewer.

Results

Of the total, 769 (94.4%) PLHIV were screened for tuberculosis, among which 212 (27.6%) were found to be positive for active tuberculosis. Among 557 (72.4%) individuals eligible for IPT, only 300 (53.9%) were provided IPT; 257 (46.1%) eligible PLHIV were not provided IPT. Resident (adjusted odds ratio [AOR] 5.6), those who didn’t attend school (AOR 4.0), primary school (grade 1-8) (AOR 3.2), and secondary school (grade 9-12) (AOR 4.2) were significantly associated with the likelihood of tuberculosis infection.

Conclusion

The present study findings demonstrated that tuberculosis screening for PLHIV at West Shewa Zone public health facilities was improved in comparison with reports from many African countries and other parts of Ethiopia. The IPT implementation rate fell short of both national and WHO guidelines, notwithstanding this improvement. In the study area, diagnostic methods for tuberculosis and existing preventive measures should be improved overall.

Introduction

Mycobacterium tuberculosis is the pathogen bacterium responsible for tuberculosis (TB) development. In 2022, tuberculosis was the second leading cause of death from a single infectious agent, following COVID-19. and was the main killer of individuals living with HIV [1,2]. Among people living with HIV, the risk of developing tuberculosis is 20–37 times higher [3]. Approximately 10.6 million new TB cases were reported globally, reflecting an incidence rate of 133 cases per 100,000 population, with 6.3% of individuals living with HIV. Tuberculosis deaths totaled 1.3 million, including an estimated 167,000 among HIV-positive individuals, predominantly occurring in the African Region (68%). The TB mortality rate among HIV-positive individuals in Africa was 9.5 per 100,000. In 2022, the WHO noted 25.6 million people living with HIV in Africa, with 167,000 deaths attributed to TB-HIV co-infection. The region accounted for 73% of global TB-HIV cases and 81% of deaths in 2019 [2,4].

Ethiopia is among the 30 countries with the highest rates of both TB and TB/HIV co-infection in the world with the overall mortality-weighted prevalence of TB-HIV co-infection was 15.27%. The WHO Global TB Report 2021 estimated a TB incidence rate of 132 cases per 100,000 population and a TB incidence rate of 8.6 per 100,000 among HIV-positive individuals in Ethiopia [5]. The WHO and the Ethiopian Federal Ministry of Health have jointly developed and suggested three specific actions related to TB and HIV within the framework of essential services for preventive measures, medical care, and therapies for HIV and tuberculosis (TB). Implementing these activities incorporates the delivery of TB and HIV services by applying “the three I’s,” which include intensive case finding for tuberculosis, administering isoniazid preventive therapy, and establishing infection prevention measures within healthcare facilities [6,7]. Isoniazid preventive therapy (IPT) serves as a crucial public health strategy aimed at reducing the incidence of tuberculosis in people living with HIV [8]. Despite the issuance of this commendation, merely 2.3 million people have undergone screening for tuberculosis, with only 178,000 being provided with isoniazid preventive therapy [9].

In 2007, Ethiopia started implementing IPT; however, due to several obstacles, including stigma, accessibility to medical facilities, adverse drug reactions, and a lack of IPT training, social support, supportive supervision, good client-provider communication, standard operating procedures, quality adherence counseling, and patient registers, the program’s implementation has remained very low [10–12].

To avert the development of a clinical tuberculosis illness, Isoniazid preventive therapy is provided to people with HIV who have a recurrent tuberculosis infection [13].

The most crucial step that comes before deciding to start IPT is screening to rule out active TB in patients who are HIV positive. In adolescents and adults with HIV infection, the regimen for TB preventive therapy is isoniazid 300 mg pyridoxine 50 mg (vitamin B6) daily for at least 6 months, as recommended by the WHO [14,15]. For HIV-positive patients who were confirmed negative for TB, the administration of IPT is deemed effective since it significantly reduces the likelihood of TB, with a risk reduction ranging from 33% to 67% throughout one to nineteen years [15–17].

Despite significant advancements in targeting individuals affected by TB, the success of initiatives aimed at reducing the incidence of TB among those infected with HIV remains considerably below the goals outlined in the global strategy to eliminate TB [9]. There is inadequate data on the extent to which progress has been made in implementing IPT among eligible people living with HIV, particularly in Ethiopia. Thus, in this study, we aimed to assess TB screening coverage and IPT among PLHIV in the west Shewa zone of Oromia Regional State, Ethiopia.

Methods

Study area

We conducted a facility-based cross-sectional study among PLHIV & following their HIV/AIDS care and support from January to February 2019 at public health institutions in the West Shewa zone, Oromia regional states. Ambo town is the capital city of the west Shewa zone and is located 115km away from Addis Ababa, the capital of Ethiopia [18].

Study design, sample size, and sampling procedure

In this study, we included randomly selected adult PLHIV who were following their HIV/AIDS care and support at public health facilities and available during the data collection period. We determined sample size using a single population proportion formula taking 39% of the proportion of active TB among PLHIV [19] and a 95% confidence interval, 5% margin of error, and 10% nonresponse rate, and considering the design effect, the total sample size calculated and used in this study was 815.

Hence out of 28 public health facilities providing HIV/AIDS care and support (HCT and ART services) in zone 13 were selected by simple random sampling techniques and proportional sample size allocation depending on the HIV patient load in each health facility. The HIV registration books determined the total number of patients in each healthcare facility. Finally using systematic random sampling, samples were selected from the logbooks of PLHIV (Fig 1).

Fig 1. Schematic presentation of sampling technique of public health facilities providing HIV/AIDS care and support (HCT and ART services) selected by Simple random sampling in districts of West Shewa Zone, Oromia, Ethiopia, 2019.

Fig 1

Data collection tool

A structured questionnaire was used to collect data via the interviewer administer approach. After reviewing relevant literature, the tool was adapted from standardized WHO guidelines, and prepared for monitoring & evaluation of TB/HIV activities [3]. The interview was conducted in a private room following the provision of their HIV/AIDS care and support services. Full informed consent was obtained from all eligible participants after explaining the study’s objectives to them. After obtaining informed consent, data collectors administered a questionnaire to respondents in their language. In addition to the interview, patient records were reviewed immediately after the interview to increase the validity of information and eliminate patient recall bias. Information was collected on the client’s experience with the TB/HIV service provision & their status. Data collection was conducted by Nurses with close supervision by the principal investigator.

Data management and analysis

The data analysis was done using SPSS version 21.0 software and we used descriptive analysis, such as frequency and percentage, to describe the socio-demographic characteristics of participants. Binary logistic regression was employed to conduct both bivariate and multivariate analyses to determine the factors linked to tuberculosis infection among people living with HIV. Candidate variables in the final model (multivariate binary logistic regression) were identified using a binary logistic regression model with P <  0.25; in the final model, multiple logistic regressions were used to determine the independent effect of each explanatory variable on the study variable, with significance set to P <  0.05. The Institutional Review Board of Ambo University College of Health Science and Referral Hospital granted ethical approval.

Algorithm for TB screening among adults and adolescents PLHIV

The national ART guidelines clearly state that all patients attending ART centers should be actively screened for TB. Patients with HIV who have untreated or undetected tuberculosis can visit ART facilities for care. Therefore, active efforts toward intensified TB case finding at ART centers are critical for early detection and treatment of TB. A clinical algorithm should be used to routinely and actively screen adults and adolescents living with HIV/AIDS for tuberculosis (TB). People who do not exhibit any of the symptoms, such as a current cough, fever, weight loss, or night sweats, are not likely to diagnosis positive tuberculosis and should be considered for isoniazid preventive therapy (IPT). Individuals who report any one of the above symptoms are suspected of having active TB and should be assessed for TB and other co-infections.

But before starting IPT, the patient should be evaluated for any contraindications; after that, IPT is given right away. IPT is collected every month by the individual for daily use. Every visit should involve a side effect check and counseling regarding adherence for each patient. According to Ethiopian national guidelines, a tuberculosis skin test (TST) is unnecessary to initiate IPT in PLHIV. People living with HIV who receive a positive result from the Tuberculin Skin Test (TST) are likely to gain greater advantages from Isoniazid Preventive Therapy (IPT); therefore, TST can be utilized, when possible, to identify these individuals (Fig 2) [20].

Fig 2. The algorithm for TB screening in adult and adolescent HIV-positive settings with limited resources and a high prevalence of HIV [20].

Fig 2

Acid-fast bacillus (AFB) tests and chest X-rays are common diagnostic tools used to detect active TB among PLHIV at the studied health facilities. If PLHIV reports any symptoms that point to an ongoing TB lung infection, regardless of how long they have been present during a visit to the hospital or other healthcare setting, AFB testing is advised [18].

Terms and operational definitions

The Three I’s.

To reduce the burden of TB disease among people living with HIV There are three activities, known as the “Three I’s,” that those providing care to people with HIV should do to protect them from active TB, help prevent active disease from developing, and to identify active TB disease early and improve the chances of cure:

ICF.

Intensified Case Finding for TB means regularly screening all people with or at high risk of HIV or in congregate settings who have active TB.

IPT.

Isoniazid Preventive Therapy for TB can safely be given to people living with HIV without TB disease, reducing the risk of developing TB.

Public and patient involvement

This study does not include any patients or the public. Patients were not asked for feedback on the study’s design, nor were they involved in creating outcomes that were pertinent to them or in interpreting the findings. The dissemination plan was developed without the patients’ input.

Ethical clearance and participation consent

Ethical clearance was obtained from the Institutional Review Board of Ambo University College of Health Sciences and Referral Hospital, and an official letter of cooperation was sent to each health facility included in the study. Written and signed informed consent was obtained from the study subjects after explaining the objectives and procedures of the study and their right to participate or to withdraw at any time during the interview. The Research and Ethical Review Committee also approved its ethical issues as no procedure affected the study subject and the data was used only for research purposes. For this purpose, a one-page consent form was attached to each questionnaire’s cover page, stating the study’s general purpose and confidentiality issues, which, before the interview, the data collectors discussed. Lastly, we attest that the Declaration of Helsinki was followed during this investigation.

Results

Characteristics related to the socio-demographic profile of individuals living with HIV

A total of 815 study participants participated in this study making a response rate of 100%. The mean age of the respondents was 39.22 ( ± 10.51 SD) years, and almost more than half of the respondents, 541 (66.4%) were in the age group of 30-49 years. The majority of the study participants, 719 (88.2%) were Oromo by ethnicity, 444 (54.5%) of them were Orthodox Christian followers, and 420 (51.5%) of them were rural residents. Of the 815 PLHIV, 421 (51.7%) were male and 394 (48.2%) were female patients; 455 (55.8%) patients were married and 149 (18.3%) were divorced.

Most respondents, 314 (38.5%) have attended primary education and 251 (30.8%) had no formal education. Among the remaining PLHIV, 150 (18.4%) had completed secondary school (grades 9–12) and 100 (12.3%) were diploma and above. Regarding the study participants’ jobs, 198 people (24.3%) were farmers, 164 people (20.1%) were without employment, 152 people (18.7%) were domestic workers, 135 people (16.6%) had employment, 112 people (13.7%) were merchants, and 54 people (6.6%) were students (Table 1).

Table 1. The socio-demographics of people living with HIV at Public Health Facilities of Central Ethiopia, 2019.

Variables (n = 815) Categories Frequency Present
Sex of Client Male 421 51.7%
Female 394 48.3%
Marital status Married 455 55.8%
Single 118 14.5%
Divorced 149 18.3%
Widowed 93 11.4%
Age 18–29 135 16.6%
30–39 269 33.0%
40–49 272 33.4%
>=50 139 17.1%
Educational Status Illiterate 251 30.8%
Primary school (1–8) 314 38.5%
Secondary school (9–12) 150 18.4%
High school diploma & above 100 12.3%
Occupational status Employed 135 16.6
Un-employed 164 20.1
Merchants 112 13.7
Farmer 198 24.3%
Student 54 6.6%
Housewife 152 18.7%
Ethnicity Oromo 719 88.2%
Amhara 64 7.9%
Others 32 3.9%
Religion Orthodox 444 54.5%
Protestant 299 36.7%
Wakefata 34 4.2%
Muslim 32 3.9%
Catholic 6 0.7%
Total 815 100.0
Residences Urban 395 48.5%
Rural 420 51.5%
Total 815 100%

The magnitude of TB screening and IPT among people living with HIV

Of the total, 769 (94.4%) PLHIV were provided TB screening services, among which 212 (27.6%) reported a positive diagnosis for active tuberculosis from the time they began receiving HIV/AIDS care and supplementary assistance; to receive TB treatment, each of these individuals was registered in the TB clinic. Among 557 (72.4%) patients with HIV who were eligible for IPT (screened for tuberculosis and found to be negative) only 300 (53.9%) were provided IPT; 257 (46.1%) patients who were eligible for IPT were not provided IPT for unknown reasons. And more than half of the eligible patients for IPT, 316 (56.7%) were not knowledgeable about eligibility for IPT. Of those patients provided with IPT, 300 (100%) were counseled on IPT utilization, 300 (100%) known from where they collect INH, and the majority, 211(70.3%) were knowledgeable about the duration of IPT utilization. Regarding TB disease classification, 212(100%) of the patients were Pulmonary positive, 185 (87.3%) were new TB disease category, and nearly half 111 (52.4%) completed treatment.

Majority of the patients, 753 (92.4%) were not admitted at least once for HIV/AIDS, 598(77.8%) were screened for TB after diagnosed for HIV, 204 (96.2%) were diagnosed by AFB (microscopy), 267 (32.8) were >  500 CD4 counts during data collection, 183 (22.5%) were > 500 CD4 counts at HIV diagnosis, and 323(39.6%) were 200 - 350 CD4 counts at ART initiation (Table 2).

Table 2. Magnitude of TB screening and IPT among people living with HIV in Central Ethiopia, 2019.

Variables Categories Frequency Present
Screened for TB Yes 769 94.4%
No 46 5.6%
Total 815 100%
Active TB diagnosis Yes (+ve) 212 27.6%
No (-ve) 557 72.4%
Total 769 100%
IPT Prophylaxis given Yes 300 53.9%
No 257 46.1%
Total 557 100%
Method of TB Diagnosis AFB (microscopy) 204 96.2%
Chest x-ray 8 3.8%
Total 212 100%
Time of screened for TB Before being diagnosed with HIV 171 22.2%
After being diagnosed with HIV 598 77.8%
Total 769 100%
Admitted to hospital at least once for HIV/ADS Yes 62 7.6%
No 753 92.4%
Total 815 100%
Knowledgeable about eligibility for IPT Yes 241 43.3%
No 316 56.7%
Total 557 100%
Duration of IPT 1–2 months 65 21.7%
3–4 months 24 8.0%
>= 5 months 211 70.3%
Total 300 100%
From where INH was collected HIV care clinic 300 100%
Counselled on IPT Yes 300 100%
Total 300 100%
Current CD4 counts  < 200 93 11.4%
200–350 251 30.8%
351–500 204 25.0%
 > 500 267 32.8%
Total 815 100%
CD4 counts at HIV diagnosis  > 500 183 22.5%
200-500 367 45.0%
<200 265 32.5%
Total 815 100%
CD4 counts at ART initiation >350 253 31.0%
200-350 323 39.6%
 < 200 239 29.3%
Total 815 100%
TB disease Classification Pulmonary positive 212 100%
TB disease Category New 185 87.3%
Relapse 27 12.7%
Total 212 100%

Active TB-related factors among people living with HIV

After adjusting for relevant confounding variables, the outcomes of the multivariate logistic regression model revealed that only residency and education had an independently significant relationship with tuberculosis infection.

Hence, rural resident clients were 5.9 times more likely to develop M. tuberculosis infection than their urban counterparts (AOR 5.6; 95% CI 1.73-19.14; P <  0.05), and PLHIV those who didn’t attend school, primary school (grade 1-8), and secondary school(grade 9-12) were 4.0, 3.2 and 4.2 times more likely to have active TB, respectively, than those diploma and above (AOR 4.0; 95% CI 1.84-8.6; AOR 3.2: 95% CI: 1.5-6.8; AOR 4.2: 95% CI: 2.0-9.4; P <  0.05) (Table 3).

Table 3. Multivariable logistic regression analysis for predicting the risk of tuberculosis infections among HIV-positive people in Central Ethiopia, 2019.

Variable (n = 769) Categories COR (95% CI) AOR (95% CI) P-Value for
(AOR)
Sex Male 1.3 (0.93–1.75) 1.0(0.7–1.5) 0.220
Female 1.00+ 1.00+
Age 18–29 2.84 (1.6–5.1) * 2.8 (0.95–5.32) 0.142
30–39 1.4 (0.91–2.235) 1.3 (0.79–2.1) 0.282
40–49 1.3 (0.84–2.04) 1.35 (0.85–2.1) 0.179
>=50 1.00+ 1.00+
Marital Status Married 1.03 (0.75–1.4) 1.3 (0.84–1.91) 0.515
Others* 1.00+ 1.00+
Education Illiterate 2.2 (1.3–362) *  4.0 (1.84–8.6) * 0.000
Elementary (1–8) 1.8 (1.13–3.0) *  3.2 (1.5–6.8) *  0.001
Secondary (9–12) 2.21 (1.3–3.94) *  4.2 (1.9–9.4) *  0.001
Diploma & above 1.00 +  1.00+ 
Residence Rural 2.0(1.4–2.8) *  5.6 (1.73–19.14) *  0.000
Urban 1.00+  1.00+ 
Occupational status Employed 0.51 (0.33–0.85) *  1.3 (0.62–2.63) 0.589
Unemployed 0.4 (0.26–0.62) *  0.4 (0.22–0.6) 0.121
Farmer 0.5 (0.31–0.71) *  0.82 (0.50–1.33) 0.331
Others** 1.00+  1.00+ 
+

The group of references.

* P <  0.05. Confidence interval (CI), crude odds ratio (COR), adjusted odds ratio (AOR),

*others  (single divorced, widowed),

**others (merchant, students, house wife).

Discussion

In this study, we found that 94.4% of PLHIV had been screened by healthcare providers for the usual signs and symptoms of TB, using a clinical algorithm. Our research revealed that people living with HIV received more tuberculosis screenings than those studied in Harar by Geleto et al. The number stated that 75.2% of people living with HIV were screened for tuberculosis [21].

Our findings were also somewhat higher than those in Addis Ababa reported by Denegetu and Dolamo (92.8%) and by Wesen and Mitike in which 87.9% of people with HIV/AIDS were offered TB screening [22,23]. In a national survey conducted in Ethiopia, 71% of people with HIV/AIDS were offered TB screening, which is also lower than our results [24]. Similarly, a study on TB/HIV integration services in Sub-Saharan Africa indicated that only 64% of newly registered people with HIV were offered TB screening [14].

The fact that a sizable percentage of PLHIV had TB screening is optimistic about the results of this study. This increment over time might be attributed to the improvement in HIV/TB treatment and care services at the study health facilities. The West Sheswa zone is also the largest zone of the Oromia regional state, in which health facilities are expanding rapidly, with an increased number of trained healthcare providers to meet the needs of high-risk populations. Our study’s findings were somewhat inferior to those of a study conducted in northern Ethiopia, where 98.2% of people living with HIV received tuberculosis screening [25] in addition to the findings of another study in Ethiopia where 96% of patients with HIV enrolled in HIV care were screened for TB [26]. The findings of our study were also lower than those conducted in southwest Ethiopia, which found that 99.7% of PLHIV had been screened by healthcare providers for the usual signs and symptoms of TB, using a clinical algorithm. [27].

Our study findings showed that 212 (27.6%) patients with HIV infection were diagnosed with active TB during their follow-up HIV care. In this study, we found a lower proportion of active TB among HIV-positive people than those from studies conducted in other parts of Ethiopia and in some developed countries, in Ethiopia (39.0%), in Harar (29.8%), in Hong Kong (39%), and Pakistan (30.2%) [19,21,28,29]. The findings of our study showed that, compared to other regions of Ethiopia and several affluent nations, a substantially larger percentage of PLHIV received an active TB diagnosis throughout their HIV treatment and follow-up care, southwest Ethiopia, 8.3%, Addis Ababa in 2008 and 2011 (15.6% and 10.4%, respectively), Georgia (22%), in northeast Ethiopia (24.3%) [23–25,27,30]. These differences might be attributed to false negatives reported for AFB testing and chest X-rays in diagnostic services. Additionally, inconsistent active TB diagnostics might result from inadequate diagnostic equipment, poor microscopy quality, untrained healthcare providers, substandard laboratory practices, and insufficient quality control measures, particularly in resource-limited settings.

The research carried out in Addis Ababa found a modest proportion of co-infection: 32 (7%) HIV-positive individuals also had positive testing for active tuberculosis [31]. The detection rates in our study [32] are higher than those in a German study of 11,693 people infected with HIV, where 233 (2%) of the participants were found to have active tuberculosis, 62 at enrollment, and 171 during subsequent follow-up visits [32].

We found that among 557 clients eligible for IPT, only 300 (53.9%) were offered IPT during follow-up HIV/AIDS care. This is lower than the rate reported in southwest Ethiopia and Harar; where 66.5% and 78.7% of PLWHI were offered IPT during follow-up HIV/AIDS care respectively [21,27]. However, we found that our findings were greater than those of two previous studies conducted in Ethiopia, where 39% of eligible people had started IPT, and in Addis Ababa, where 28.7% of people living with HIV were administered Isoniazid preventive therapy [19,23].

In line with the global report on TB, the statistical data show that the IPT coverage is 15.1% in Ethiopia, 5.4% in Bangladesh, 8.0% in Myanmar, and only 3.0% in Nigeria [33]. We found that a significant percentage of eligible people living with HIV had started IPT throughout HIV subsequent follow-up, in contrast to the majority of findings from Ethiopia and other nations.

The current high rates of IPT among research participants may point to the subsequent improvements in TB/HIV collaboration services; however, these findings could also be explained by variations in study design, sample size, and study environment between studies.

In our study, education and residence showed a statistically significant association with the likelihood of active TB among PLHIV. Education significantly affected active TB, consistent with other study findings from southern Ethiopia [34]. A possible explanation might be that educated people have better health service-seeking behavior, frequent visits to health facilities for services, and are engaged more in disease prevention and health promotion. Our study findings indicated that PLHIV those who lived in rural residences were at higher risk for active TB than those who lived in urban residences. This might be owing to people living in urban residents having more access to health information, health care services, and other infrastructure that enables them to fight TB.

Conclusion

The present study demonstrated that the implementation of TB screening among individuals with HIV infection in the west Shoewa zone was higher than that in many African countries, as well as in other parts of Ethiopia. Additionally, education and residence were identified as factors that determine the likelihood of active TB among PLHIV. Nevertheless, despite advancements, IPT implementation fell short of national and WHO guidelines.

In general, putting into practice the current national and World Health Organization recommendations could improve tuberculosis diagnosis techniques and accessible prevention strategies. Ongoing support of healthcare workers through continuous capacity building and experience sharing can serve to advance the implementation of TB screening and IPT initiation.

Additionally, service providers must be part of the solution by providing targeted patient education and counseling (to rural residents along with less schooled people living with HIV) to raise knowledge of the advantages and significance of IPT and enhance its acceptance. Additionally, collaborative research comprising several regions of the country including health facilities and healthcare professional-related factors is recommended to provide a more balanced view of active TB, IPT provision, and potential risk factors among patients with HIV infection.

Supporting information

S1 File. TBHIV original raw data.

(SAV)

pone.0319676.s001.sav (43.5KB, sav)

Acknowledgments

We express our gratitude to Ambo University College of Health Sciences and Referral Hospital, as well as the data collectors, study participants, and any other individuals who played a formal or informal role in the successful completion of this research.

Data Availability

The dataset used and analyzed throughout this study is uploaded as Supplementary Information.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.World Health Organization. Global Tuberculosis Report 2012 on Tuberculosis, epidemiology, Tuberculosis, Pulmonary prevention, and control, Tuberculosis economic, directly observed therapy, Treatment outcome, National Health programs organization and administration, and Statistics. WHO. ISBN 97892 4 156450 2. [Google Scholar]
  • 2.World Health Organization. Global tuberculosis report 2022: 2022. [Google Scholar]
  • 3.World Health Organization. WHO Global Tuberculosis Control: a short update to the 2010 report. December 2009. Geneva, Switzerland: World Health Organization; 2010. [Google Scholar]
  • 4.World Health Organization. Global Tuberculosis Report. 2020. [Google Scholar]
  • 5.World Health Organization. Global tuberculosis report 2021. 2021. [Google Scholar]
  • 6.Beshaw MA, Balcha SA, Lakew AM. Effect of isoniazid prophylaxis therapy on the prevention of tuberculosis incidence and associated factors among HIV infected individuals in northwest Ethiopia: retrospective cohort study. HIV AIDS (Auckl). 2021;13:617–29. doi: 10.2147/HIV.S301355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.World Health Organization. WHO policy on collaborative TB/HIV activities. Guidelines for national programs and other stakeholders. World Heal Organ Doc. 2012. WHO/HTM/TB. 1–34. [PubMed] [Google Scholar]
  • 8.WHO/UNAIDS. WHO and UNAIDS policy statement on preventive therapy against TB in people living with HIV. Weekly Epidemiological Record 1999;74:385–400.10611855 [Google Scholar]
  • 9.Nachega J, Coetzee J, Adendorff T, Msandiwa R, Gray GE, McIntyre JA, et al. Tuberculosis active case-finding in a mother-to-child HIV transmission prevention programme in Soweto, South Africa. AIDS. 2003;17(9):1398–400. doi: 10.1097/00002030-200306130-00018 [DOI] [PubMed] [Google Scholar]
  • 10.FMOH. Implementation guideline for TB/ HIV collaborative activities in Ethiopia. Addis Ababa: Federal Ministry of Health; 2008. [Google Scholar]
  • 11.World Health Organization. Global tuberculosis report. World Health Organization; 2014. [Google Scholar]
  • 12.Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 Suppl 5:S57–65. doi: 10.1097/01.aids.0000391023.03037.1f [DOI] [PubMed] [Google Scholar]
  • 13.Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1997;337(5):315–20. doi: 10.1056/NEJM199707313370505 [DOI] [PubMed] [Google Scholar]
  • 14.The Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Fund Information Note: TB/HIV Collaborative Activities. Available from: http://www.stoptb.org/assets/2012/02/21/global/TB/HIVCollaborativeActivities. [Google Scholar]
  • 15.World Health Organization. Guidelines for Intensified Tuberculosis Case-Finding and IPT for PLHIV in Resource-Constrained Settings. Geneva, Switzerland: WHO; 2011. [Google Scholar]
  • 16.Aït-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang C-Y, et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis. 2009;13(8):927–35. [PubMed] [Google Scholar]
  • 17.Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827–30. doi: 10.1164/arrd.1979.119.5.827 [DOI] [PubMed] [Google Scholar]
  • 18.West Shewa Zonal Health Office Annual Report. 2018.
  • 19.Adelman MW, Tsegaye M, Kempker RR, Alebachew T, Haile K, Tesfaye A, et al. Intensified tuberculosis case finding among HIV-infected persons using a WHO symptom screen and Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015;19(10):1197–203. doi: 10.5588/ijtld.15.0230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.FMOH Guideline National for Comprehensive HIV Prevention, Care and Treatment. 2017:93. [Google Scholar]
  • 21.Geleto A, Abate D, Egata G. Intensified tuberculosis case finding, implementation of isoniazid preventive therapy and associated factors among people living with human immunodeficiency virus at public health facilities of Harari Region, Eastern Ethiopia: a cross-sectional study. Int J Health Sci (Qassim). 2017;11(1):1–8. [PMC free article] [PubMed] [Google Scholar]
  • 22.Denegetu AW, Dolamo BL. Tuberculosis case finding and isoniazid preventive therapy among people living with HIV at public health facilities of Addis Ababa, Ethiopia: a cross-sectional facility based study. BMC Public Health. 2014;14:52. doi: 10.1186/1471-2458-14-52 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wesen A, Mitike G. Screening and case detection for tuberculosis among people living with HIV in Addis Ababa, Ethiopia. Ethiop Med J. 2009;47(2):109–15. [PubMed] [Google Scholar]
  • 24.Ethiopian Public Health Institute (EPHI), Ministry of Health (MOH) National TB/ HIV Sentinel Surveillance Annual Report, (July 2014-June 2015). Available from: http://www.ephi.gov.et/images/pictures/Final_National_TBHIV_Sentinel_Surveillance_OCT_20_FE2015_20.pdf. [Google Scholar]
  • 25.Mekonnen D, Derbie A, Desalegn E. TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study. BMC Res Notes. 2015;8:666. doi: 10.1186/s13104-015-1664-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.WHO Country Office for Ethiopia. Tuberculosis Update in Ethiopia. Progress in 2014. Addis Ababa; 2015. Available from: http://www.afro.who.int/en/Ethiopia/who-country-office-ethiopia.html [Google Scholar]
  • 27.Aboma M, Dida N. Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, southwest Ethiopia: a retrospective study design. J Int Med Res. 2021;49(9):3000605211046133. doi: 10.1177/03000605211046133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chan CK, Alvarez Bognar F, Wong KH, Leung CC, Tam CM, Chan KCW, et al. The epidemiology and clinical manifestations of human immunodeficiency virus-associated tuberculosis in Hong Kong. Hong Kong Med J. 2010;16(3):192–8. [PubMed] [Google Scholar]
  • 29.Memon AR, Memon MA, Altaf A, Shah SA, Zuberi BF, Qadeer R, et al. Frequency of dual tuberculosis/human immunodeficiency virus infection in patients presenting at tertiary care centers at karachi. J Coll Physicians Surg Pak. 2007;17(10):591–3. doi: 10.2007/JCPSP.591593 [DOI] [PubMed] [Google Scholar]
  • 30.Gabunia P, Salakaia A, Kiria N, et al. TB/ HIV co-infection in Georgia. Georgian Med News. 2008:7–10. [PubMed] [Google Scholar]
  • 31.Shah S, Demissie M, Lambert L, Ahmed J, Leulseged S, Kebede T, et al. Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr. 2009;50(5):537–45. doi: 10.1097/QAI.0b013e318196761c [DOI] [PubMed] [Google Scholar]
  • 32.Karo B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, Fiebig L, et al. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis. 2014;14:148. doi: 10.1186/1471-2334-14-148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.World Health Organization (WHO). WHO 3 I’s Meeting: Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT) and active TB Control (IC) for people living with HIV: Report of a WHO Joint HIV and TB Department Meeting. Available from: http://www.who.int/hiv/2012/10/23/meetingreport/WHO_3Is_meeting_report.pdf. [Google Scholar]
  • 34.Fekadu S, Teshome W, Alemu G. Prevalence and determinants of Tuberculosis among HIV infected patients in south Ethiopia. J Infect Dev Ctries. 2015;9(8):898–904. doi: 10.3855/jidc.5667 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Rebecca F Baggaley

4 Dec 2024

PONE-D-24-31425Tuberculosis Screening, Isoniazid Preventive Therapy and Associated Factors Among People Living with HIV at Public Health Facilities of Central EthiopiaPLOS ONE

Dear Dr. Aboma,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 18 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Rebecca F. Baggaley

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In the online submission form, you indicated that [The dataset used and analyzed throughout this study is available from the corresponding author upon reasonable request.]. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.

3. Please include a separate caption for each figure in your manuscript.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I would like to commend the authors for conducting this important research on a topic of great relevance for the continued reduction of TB cases and deaths. This study provides valuable insights into the TPT cascade and contributes to existing knowledge on this critical area of TB prevention.

However, I have a few key concerns that need to be addressed:

Major Concerns:

Research Structure: The study appears to have two distinct components: the first focuses on patient progression through the early stages of the TPT cascade (screening for active TB, determining TPT eligibility, and providing TPT), while the second examines factors associated with active TB. The title does not fully reflect the second part of the study, and it seems somewhat disconnected from the first. It might be more coherent to analyze factors related to TB screening and TPT provision rather than factors associated with active TB.

Terminology: Some terms are used incorrectly, making the paper harder to understand. For instance, "TB infection" is used instead of "active TB," or "recurrent tuberculosis infection". Improving the language throughout the paper will enhance clarity.

Conclusions Not Supported by Results: Several conclusions in the manuscript are not adequately supported by the data presented (lines 288-289, 296, 299-300). Please revisit these sections to ensure that the conclusions are based on the results.

Minor Revisions:

Introduction: The introduction could be shortened, and it would be helpful to update the data, using statistics from 2021 and 2022 instead of 2018 and 2020.

Aim of the Study: The phrase "progress in reducing the risk of TB" (line 88) feels inappropriate as a research aim. A more accurate aim would be "progress in implementing TPT."

Sample Size Calculation: The concept of "design effect" used in sample size calculation (line 101) is unclear. Please provide further explanation or clarification.

Figure 1: It would be more informative if the authors could display the overall number of PLHIV (People Living with HIV) in each facility and then provide the sample size for each. All the abbreviations should be added in the legend.

Patient Evaluation: It would be helpful to include information on how many patients had a positive symptom screening but did not complete further evaluation, as well as how many patients were found to have contraindications for TPT.

Diagnostic Methods: It is unclear why 551 patients were diagnosed with AFB smear while the initial screening was based on symptoms. Were all patients who were initially screened positive referred for AFB testing?

Typographical Error: There is a typographical error in the numbers; "796" is used instead of "769" in some calculations.

Table 3: I suggest restructuring Table 3. The second and third columns could be removed, and a column for p-values should be added to enhance the clarity of statistical significance.

I hope these suggestions help improve the quality and clarity of the manuscript. Best of luck with your revisions.

Reviewer #2: 1. The conclusion must mention the associated factors according to the title (‘Associated Factors Among People Living with HIV at Public Health Facilities of Central Ethiopia’).

2. This study still uses the AFB microscopy test to determine active TB. Is there no molecular rapid test available?

3. In data table 2, the CD4 variable (Current CD4 Count) should be added to group the CD4 count based on the diagnosis status of active or latent TB.

4. There were 257 (46.1%) eligible PLHIV patients who were not given IPT, please provide clear reasons for this.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Tutik Kusmiati

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Mar 10;20(3):e0319676. doi: 10.1371/journal.pone.0319676.r003

Author response to Decision Letter 1


30 Dec 2024

Author's response to Reviewers Comments

Manuscript ID: - PONE-D-24-31425

Title of Manuscript: Tuberculosis Screening, Isoniazid Preventive Therapy, and Associated Factors Among People Living with HIV at Public Health Facilities of Central Ethiopia

Authors:

1. Mecha Aboma: abomamecha@gmail.com

2. Bayisa Abdisa

3. Gudata Imana

4. Kefalew Taye

5. Gonfa Moti

6. Merob Fufa

A Point-by-point Response to Reviewer Comments to the Authors

Reviewer #1: Major Concerns:

1. Reviewer 1 Question 1. Research Structure: The study appears to have two distinct components: the first focuses on patient progression through the early stages of the TPT cascade (screening for active TB, determining TPT eligibility, and providing TPT), while the second examines factors associated with active TB. The title does not fully reflect the second part of the study, and it seems somewhat disconnected from the first. It might be more coherent to analyze factors related to TB screening and TPT provision rather than factors associated with active TB.

Authors Response 1. Yes, the comment is accepted and revised and indicated by highlighted with track change as flow: Tuberculosis Screening and Isoniazid Preventive Therapy Coverage and Factors Associated with Active TB Diagnosis Among People Living with HIV at Public Health Facilities of Central Ethiopia

2. Reviewer 1 Question 2. Terminology: Some terms are used incorrectly, making the paper harder to understand. For instance, "TB infection" is used instead of "active TB," or "recurrent tuberculosis infection". Improving the language throughout the paper will enhance clarity.

Authors Response 2. Yes, the comment is accepted and corrected and indicated by highlighting with track change as flow: TB infection" is replaced by "active TB," or "recurrent tuberculosis infection"

3. Reviewer 1 Question 3. Conclusions Not Supported by Results: Several conclusions in the manuscript are not adequately supported by the data presented (lines 288-289, 296, 299-300). Please revisit these sections to ensure that the conclusions are based on the results.

Authors Response 3: Yes, the comment is accepted and revised and indicated by highlighted with track change lines 306-3010 and 3017-3025

Minor Revisions:

4. Reviewer 1 Question 4. Introduction: The introduction could be shortened, and it would be helpful to update the data, using statistics from 2021 and 2022 instead of 2018 and 2020.

Authors Response 4. Yes, the comment is accepted and revised and indicated by highlighted with track change, Lines 41-65, 69-70, 73-74, and 76-79

5. Reviewer 1 Question 5. Aim of the Study: The phrase "progress in reducing the risk of TB" (line 88) feels inappropriate as a research aim. A more accurate aim would be "progress in implementing TPT."

Authors Response 5. Yes, the comment is accepted and revised and indicated by highlighted with track change as flows: There is inadequate data on the extent to which progress has been made in implementing IPT among eligible people living with HIV, particularly in Ethiopia. Line 100-104

6. Reviewer 1 Question 6. Sample Size Calculation: The "design effect" concept used in sample size calculation (line 101) is unclear. Please provide further explanation or clarification.

Authors Response 6. Yes, the comment is accepted and revised and indicated by highlighted with track change as flows: To eliminate the design effect and have an adequate sample size, the sample size was doubled, and 10% of the total sample size was added to account for the non-response rate. The study was conducted in the West Shewa Zone, where 13 public health facilities were selected from 28 eligible health facilities located at the district level. People living with HIV (PLHIV) were then selected from the health facilities in each district.

7. Reviewer 1 Question 7. Figure 1: It would be more informative if the authors could display the overall number of PLHIV (People Living with HIV) in each facility and then provide the sample size for each. All the abbreviations should be added to the legend.

Authors Response 7. Yes, the comment is accepted, and the overall number of PLHIV (People Living with HIV) in each facility and the sample size for each health facility are included in Figure 1. And all the abbreviations added in the legend

8. Reviewer 1 Question 8. Patient Evaluation: It would be helpful to include information on how many patients had a positive symptom screening but did not complete further evaluation, as well as how many patients were found to have contraindications for TPT.

Authors Response 8. Yes, the comment is accepted and it was one of the limitations of this study, however contraindication for IPT was asked but all of the study participants responded that they had not reported any contraindication regarding IPT, however not included in the result.

9. Reviewer 1 Question 9. Diagnostic Methods: It is unclear why 551 patients were diagnosed with AFB smear while the initial screening was based on symptoms. Were all patients who were initially screened positive referred for AFB testing?

Authors Response 9. Thank you, the comment is accepted and corrected, indicated by highlighting with track change. It was a typographical error, corrected to 204 patients were diagnosed with AFB. Line 217, Table 2

10. Reviewer 1 Question 10. Typographical Error: There is a typographical error in the numbers; "796" is used instead of "769" in some calculations.

Authors Response 10. Thank you, the comment is accepted and corrected, indicated by highlighting with track change. It was a typographical error, corrected to 769. Table 2

11. Reviewer 1 Question 11. Table 3: I suggest restructuring Table 3. The second and third columns could be removed, and a column for p-values should be added to enhance the clarity of statistical significance.

Authors Response 11. The comment is accepted and corrected, indicated by highlighting with track change and P-Values are added

Reviewer #2

1. Reviewer 2 Question 1. The conclusion must mention the associated factors according to the title (‘Associated Factors Among People Living with HIV at Public Health Facilities of Central Ethiopia’).

Authors Response 1. The comment is accepted and corrected, indicated by highlighting with track change, and the associated factors were mentioned in the conclusion. Line 306-307

2. Reviewer 2 Question 2: This study still uses the AFB microscopy test to determine active TB. Is there no molecular rapid test available?

Authors Response 2. Yes, the comment is accepted. However, Acid-fast bacillus (AFB) tests and chest X-rays are common diagnostic tools used to detect TB infection among PLHIV at the studied health facilities (in the West Shew zone public health facilities) because molecular rapid tests were not available as indicated in the method line164-166.

3. Reviewer 2 Question 3. In data table 2, the CD4 variable (Current CD4 Count) should be added to group the CD4 count based on the diagnosis status of active or latent TB.

Authors Response 3. Yes, the comment is accepted. However, the Current CD4 count was already included in Table 2 and lines 218-120. Also, the National TB guideline in Ethiopia recommends IPT for all HIV-infected people who are unlikely to have active TB, regardless of CD4. CD4 count is not required to initiate Isoniazid Preventive Therapy (IPT) for people living with HIV (PLHIV) in Ethiopia. Similarly, Ethiopia adopted the “Universal Test and Treat” strategy to its national policy in 2016 to put all people living with HIV/AIDS (PLHIV) on antiretroviral therapy (ART) regardless of their World Health Organization (WHO) clinical stage or CD4 cell count level

4. Reviewer 2 Question 4. There were 257 (46.1%) eligible PLHIV patients who were not given IPT, please provide clear reasons for this.

Authors Response 4: Yes, the comment is accepted. However, most of these concerns were addressed in the discussion part lines 278-292, and in the result part mentioned as unknown reasons line 209. Because the study was focused only on the patients and did not address the factors related to the health facility as well as healthcare professionals, thus it could be one of the limitations of this study as further study including health facilities and healthcare professional-related factors was recommended in the conclusion part in line 321-325

Attachment

Submitted filename: Author Response to Reviewewer comment TBHIV.docx

pone.0319676.s002.docx (22.9KB, docx)

Decision Letter 1

Rebecca F Baggaley

31 Jan 2025

PONE-D-24-31425R1Tuberculosis Screening, Isoniazid Preventive Therapy Coverage and Factors Associated with Active TB Diagnosis Among People Living with HIV at Public Health Facilities of Central EthiopiaPLOS ONE

Dear Dr. Aboma,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 17 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Rebecca F. Baggaley

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors,

Thank you for addressing most of the comments and clarifying the questions raised in the previous review. The manuscript has improved significantly. However, there are still a few points that remain unaddressed, particularly regarding terminology and numerical inconsistencies (comment 2 and 10 from my previous review). I would like to bring up two additional comments for your consideration:

Table 3 – It would be helpful to specify whether the reported p-values correspond to the crude or adjusted OR.

Lines 255-256 – Could you clarify whether you mean that the reported TB incidence was inflated due to false-positive AFB results? Typically, AFB testing is more prone to false negatives rather than false positives, which is the greater concern with this diagnostic method.

I appreciate your efforts in revising the manuscript and look forward to your response.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Tutik Kusmiati

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Mar 10;20(3):e0319676. doi: 10.1371/journal.pone.0319676.r005

Author response to Decision Letter 2


1 Feb 2025

2nd Round Author's Response to Reviewers' Comments

Manuscript ID: - PONE-D-24-31425

Title of Manuscript: Tuberculosis Screening, Isoniazid Preventive Therapy, and Associated Factors Among People Living with HIV at Public Health Facilities of Central Ethiopia

Authors:

1. Mecha Aboma: abomamecha@gmail.com

2. Bayisa Abdisa

3. Gudata Imana

4. Kefalew Taye

5. Gonfa Moti

6. Merob Fufa

A Point-by-point Response to Reviewer Comments to the Authors

Reviewer #1: comments, Dear Authors,

Thank you for addressing most of the comments and clarifying the questions raised in the previous review. The manuscript has improved significantly. However, there are still a few points that remain unaddressed, particularly regarding terminology and numerical inconsistencies (comment 2 and 10 from my previous review). I would like to bring up two additional comments for your consideration: Table 3 – It would be helpful to specify whether the reported p-values correspond to the crude or adjusted OR.

Lines 255-256 – Could you clarify whether you mean that the reported TB incidence was inflated due to false-positive AFB results? Typically, AFB testing is more prone to false negatives rather than false positives, which is the greater concern with this diagnostic method.

I appreciate your efforts in revising the manuscript and look forward to your response.

Authors Response. Thank you for thoroughly reviewing my paper and helping me improve its quality. Yes, all the comments are accepted and revised and indicated by highlighting with track changes as flows.

1. Reviewer comment 1: Comments 2 and 10 from my previous review).

Authors Response 1

� Yes, the comment is accepted and corrected and indicated by highlighting with track change as flow: TB infection" is replaced by "active TB throughout the document (Line 128).

� Thank you, the comment is accepted and corrected, indicated by highlighting with track change. It was a typographical error, corrected to 769 (Line 25, 420).

2. Reviewer comment 2: Table 3 – It would be helpful to specify whether the reported p-values correspond to the crude or adjusted OR.

Authors Response 2

� The comment is accepted and corrected, indicated in Table 3: The p-values correspond to the Adjusted OR and are specified in Table 3

3. Reviewer comment 3: Lines 255-256 – Could you clarify whether you mean that the reported TB incidence was inflated due to false-positive AFB results? Typically, AFB testing is more prone to false negatives rather than false positives, which is the greater concern with this diagnostic method.

Authors Response 3

Thank you, the comment is accepted and corrected, as indicated by highlighting with track change. In the first draft of the research paper, I submitted a sentence like this: “These differences might be attributed to false negatives reported for AFB testing and chest X-ray.” This typographical error likely occurred while I was editing and incorporating feedback from the editors and academic reviewers. I apologize for the typographical error; it has been corrected to "a false negative." Additionally, this statement pertains not only to the inflated active TB diagnoses reported in our study but also serves as a justification for the overall inconsistency of active TB diagnoses reported in our study compared to those reported by others, whether higher or lower than our findings. Thus, the comment has been genuinely accepted and corrected as flow (Line 255-259).

These differences might be attributed to false negatives reported for AFB testing and chest X-rays in diagnostic services. Additionally, inconsistent active TB diagnostics might result from inadequate diagnostic equipment, poor microscopy quality, untrained healthcare providers, substandard laboratory practices, and insufficient quality control measures, particularly in resource-limited settings.

Attachment

Submitted filename: Author_Response_to_Reviewewer_comment_TBHIV_auresp_2.docx

pone.0319676.s003.docx (22.5KB, docx)

Decision Letter 2

Rebecca F Baggaley

6 Feb 2025

Tuberculosis Screening, Isoniazid Preventive Therapy Coverage and Factors Associated with Active TB Diagnosis Among People Living with HIV at Public Health Facilities of Central Ethiopia

PONE-D-24-31425R2

Dear Dr. Aboma,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Rebecca F. Baggaley

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Rebecca F Baggaley

PONE-D-24-31425R2

PLOS ONE

Dear Dr. Aboma,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Rebecca F. Baggaley

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. TBHIV original raw data.

    (SAV)

    pone.0319676.s001.sav (43.5KB, sav)
    Attachment

    Submitted filename: Author Response to Reviewewer comment TBHIV.docx

    pone.0319676.s002.docx (22.9KB, docx)
    Attachment

    Submitted filename: Author_Response_to_Reviewewer_comment_TBHIV_auresp_2.docx

    pone.0319676.s003.docx (22.5KB, docx)

    Data Availability Statement

    The dataset used and analyzed throughout this study is uploaded as Supplementary Information.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES